413 related articles for article (PubMed ID: 20206139)
21. Human liver enzymes responsible for metabolic elimination of tyramine; a vasopressor agent from daily food.
Niwa T; Murayama N; Umeyama H; Shimizu M; Yamazaki H
Drug Metab Lett; 2011 Aug; 5(3):216-9. PubMed ID: 21679153
[TBL] [Abstract][Full Text] [Related]
22. In vitro metabolism of the analgesic bicifadine in the mouse, rat, monkey, and human.
Erickson DA; Hollfelder S; Tenge J; Gohdes M; Burkhardt JJ; Krieter PA
Drug Metab Dispos; 2007 Dec; 35(12):2232-41. PubMed ID: 17881661
[TBL] [Abstract][Full Text] [Related]
23. Oxidative metabolism of 5-methoxy-N,N-diisopropyltryptamine (Foxy) by human liver microsomes and recombinant cytochrome P450 enzymes.
Narimatsu S; Yonemoto R; Saito K; Takaya K; Kumamoto T; Ishikawa T; Asanuma M; Funada M; Kiryu K; Naito S; Yoshida Y; Yamamoto S; Hanioka N
Biochem Pharmacol; 2006 Apr; 71(9):1377-85. PubMed ID: 16510126
[TBL] [Abstract][Full Text] [Related]
24. The serotonergic hallucinogen 5-methoxy-N,N-dimethyltryptamine disrupts cortical activity in a regionally-selective manner via 5-HT(1A) and 5-HT(2A) receptors.
Riga MS; Bortolozzi A; Campa L; Artigas F; Celada P
Neuropharmacology; 2016 Feb; 101():370-8. PubMed ID: 26477571
[TBL] [Abstract][Full Text] [Related]
25. Cyp2D6 catalyzes 5-hydroxylation of 1-(2-pyrimidinyl)-piperazine, an active metabolite of several psychoactive drugs, in human liver microsomes.
Raghavan N; Zhang D; Zhu M; Zeng J; Christopher L
Drug Metab Dispos; 2005 Feb; 33(2):203-8. PubMed ID: 15507542
[TBL] [Abstract][Full Text] [Related]
26. Comparative aromatic hydroxylation and N-demethylation of MPTP neurotoxin and its analogs, N-methylated beta-carboline and isoquinoline alkaloids, by human cytochrome P450 2D6.
Herraiz T; Guillén H; Arán VJ; Idle JR; Gonzalez FJ
Toxicol Appl Pharmacol; 2006 Nov; 216(3):387-98. PubMed ID: 16870220
[TBL] [Abstract][Full Text] [Related]
27. Metabolism and clinical pharmacokinetics of 2-methyl-n-(2'-(pyrrolidinyl-1-ylsulfonyl)-n-[1,1'-biphenyl]-4-yl)propran-1-amine: insights into monoamine oxidase- and CYP-mediated disposition by integration of in vitro ADME tools.
Sawant Basak A; Byon W; Tseng-Lovering E; Funk C; Wood L; Lin C; Delnomdedieu M; Verhoest P; Parikh V; Cox LM; Miller E; Gao H; Obach RS
Xenobiotica; 2014 May; 44(5):438-54. PubMed ID: 24304147
[TBL] [Abstract][Full Text] [Related]
28. Influence of N-substitution of 7-methoxy-4-(aminomethyl)-coumarin on cytochrome P450 metabolism and selectivity.
Venhorst J; Onderwater RC; Meerman JH; Commandeur JN; Vermeulen NP
Drug Metab Dispos; 2000 Dec; 28(12):1524-32. PubMed ID: 11095593
[TBL] [Abstract][Full Text] [Related]
29. Bromo-dragonfly, a psychoactive benzodifuran, is resistant to hepatic metabolism and potently inhibits monoamine oxidase A.
Noble C; Holm NB; Mardal M; Linnet K
Toxicol Lett; 2018 Oct; 295():397-407. PubMed ID: 30036687
[TBL] [Abstract][Full Text] [Related]
30. Polymorphic cytochrome P450 2D6: humanized mouse model and endogenous substrates.
Yu AM; Idle JR; Gonzalez FJ
Drug Metab Rev; 2004 May; 36(2):243-77. PubMed ID: 15237854
[TBL] [Abstract][Full Text] [Related]
31. Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6.
Yu AM; Idle JR; Byrd LG; Krausz KW; Küpfer A; Gonzalez FJ
Pharmacogenetics; 2003 Mar; 13(3):173-81. PubMed ID: 12618595
[TBL] [Abstract][Full Text] [Related]
32. Cytochrome P4502D6 catalyzes the O-demethylation of the psychoactive alkaloid ibogaine to 12-hydroxyibogamine.
Obach RS; Pablo J; Mash DC
Drug Metab Dispos; 1998 Aug; 26(8):764-8. PubMed ID: 9698290
[TBL] [Abstract][Full Text] [Related]
33. Selective inhibition of the cytochrome P450 isoform by hyperoside and its potent inhibition of CYP2D6.
Song M; Hong M; Lee MY; Jee JG; Lee YM; Bae JS; Jeong TC; Lee S
Food Chem Toxicol; 2013 Sep; 59():549-53. PubMed ID: 23835282
[TBL] [Abstract][Full Text] [Related]
34. Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study.
Obach RS; Cox LM; Tremaine LM
Drug Metab Dispos; 2005 Feb; 33(2):262-70. PubMed ID: 15547048
[TBL] [Abstract][Full Text] [Related]
35. Identification of human cytochrome P450 2D6 as major enzyme involved in the O-demethylation of the designer drug p-methoxymethamphetamine.
Staack RF; Theobald DS; Paul LD; Springer D; Kraemer T; Maurer HH
Drug Metab Dispos; 2004 Apr; 32(4):379-81. PubMed ID: 15039289
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics of N,N-dimethyltryptamine in Humans.
Good M; Joel Z; Benway T; Routledge C; Timmermann C; Erritzoe D; Weaver R; Allen G; Hughes C; Topping H; Bowman A; James E
Eur J Drug Metab Pharmacokinet; 2023 May; 48(3):311-327. PubMed ID: 37086340
[TBL] [Abstract][Full Text] [Related]
37. MD 240928 and harmaline: opposite selectivity in antagonism of the inactivation of types A and B monoamine oxidase by pargyline in mice.
Fuller RW; Wong CJ; Hemrick-Luecke SK
Life Sci; 1986 Feb; 38(5):409-12. PubMed ID: 3945167
[TBL] [Abstract][Full Text] [Related]
38. The epidemiology of 5-methoxy- N, N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption.
Davis AK; Barsuglia JP; Lancelotta R; Grant RM; Renn E
J Psychopharmacol; 2018 Jul; 32(7):779-792. PubMed ID: 29708042
[TBL] [Abstract][Full Text] [Related]
39. Cytochrome b5 is a major determinant of human cytochrome P450 CYP2D6 and CYP3A4 activity in vivo.
Henderson CJ; McLaughlin LA; Scheer N; Stanley LA; Wolf CR
Mol Pharmacol; 2015 Apr; 87(4):733-9. PubMed ID: 25657337
[TBL] [Abstract][Full Text] [Related]
40. Characterization of 1-Aminobenzotriazole and Ketoconazole as Novel Inhibitors of Monoamine Oxidase (MAO): An In Vitro Investigation.
Shaik AN; LeDuc BW; Khan AA
Eur J Drug Metab Pharmacokinet; 2017 Oct; 42(5):827-834. PubMed ID: 28185143
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
